Ironwood Pharmaceuticals (IRWD) Competitors

Ironwood Pharmaceuticals logo
$4.68 -0.10 (-1.99%)
As of 02:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

IRWD vs. ABBV, IRON, IDYA, ZLAB, and VCEL

Should you buy Ironwood Pharmaceuticals stock or one of its competitors? Ironwood Pharmaceuticals's main competitors and comparable companies include AbbVie (ABBV), Disc Medicine (IRON), IDEAYA Biosciences (IDYA), Zai Lab (ZLAB), and Vericel (VCEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ironwood Pharmaceuticals compare to AbbVie?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and AbbVie (NYSE:ABBV) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Ironwood Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

In the previous week, AbbVie had 35 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 38 mentions for AbbVie and 3 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 0.94 beat Ironwood Pharmaceuticals' score of 0.54 indicating that AbbVie is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ironwood Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AbbVie
24 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Positive

Ironwood Pharmaceuticals has a net margin of 37.38% compared to AbbVie's net margin of 15.67%. Ironwood Pharmaceuticals' return on equity of -81.40% beat AbbVie's return on equity.

Company Net Margins Return on Equity Return on Assets
Ironwood Pharmaceuticals37.38% -81.40% 42.69%
AbbVie 15.67%-450.55%16.50%

70.2% of AbbVie shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ironwood Pharmaceuticals currently has a consensus price target of $6.23, suggesting a potential upside of 34.75%. AbbVie has a consensus price target of $299.62, suggesting a potential upside of 6.72%. Given Ironwood Pharmaceuticals' higher possible upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than AbbVie.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ironwood Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.57
AbbVie
0 Sell rating(s)
6 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.83

AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ironwood Pharmaceuticals$296.15M2.59$24.02M$0.905.14
AbbVie$61.16B8.11$4.23B$5.8148.32

Summary

AbbVie beats Ironwood Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Disc Medicine?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Ironwood Pharmaceuticals has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

In the previous week, Disc Medicine had 6 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 9 mentions for Disc Medicine and 3 mentions for Ironwood Pharmaceuticals. Disc Medicine's average media sentiment score of 0.81 beat Ironwood Pharmaceuticals' score of 0.54 indicating that Disc Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ironwood Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Disc Medicine
4 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, indicating a potential upside of 34.75%. Disc Medicine has a consensus target price of $125.27, indicating a potential upside of 62.96%. Given Disc Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Disc Medicine is more favorable than Ironwood Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ironwood Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.57
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.79

Ironwood Pharmaceuticals has a net margin of 37.38% compared to Disc Medicine's net margin of 0.00%. Disc Medicine's return on equity of -36.33% beat Ironwood Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ironwood Pharmaceuticals37.38% -81.40% 42.69%
Disc Medicine N/A -36.33%-32.50%

Ironwood Pharmaceuticals has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ironwood Pharmaceuticals$296.15M2.59$24.02M$0.905.14
Disc MedicineN/AN/A-$212.18M-$6.34N/A

83.7% of Disc Medicine shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Ironwood Pharmaceuticals and Disc Medicine tied by winning 8 of the 16 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to IDEAYA Biosciences?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Ironwood Pharmaceuticals currently has a consensus price target of $6.23, indicating a potential upside of 34.75%. IDEAYA Biosciences has a consensus price target of $49.55, indicating a potential upside of 88.16%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe IDEAYA Biosciences is more favorable than Ironwood Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ironwood Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.57
IDEAYA Biosciences
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80

Ironwood Pharmaceuticals has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

98.3% of IDEAYA Biosciences shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, IDEAYA Biosciences had 14 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 17 mentions for IDEAYA Biosciences and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.54 beat IDEAYA Biosciences' score of 0.13 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ironwood Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IDEAYA Biosciences
1 Very Positive mention(s)
5 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Ironwood Pharmaceuticals has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ironwood Pharmaceuticals$296.15M2.59$24.02M$0.905.14
IDEAYA Biosciences$218.71M11.64-$113.70M-$4.49N/A

Ironwood Pharmaceuticals has a net margin of 37.38% compared to IDEAYA Biosciences' net margin of -1,157.18%. IDEAYA Biosciences' return on equity of -39.78% beat Ironwood Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ironwood Pharmaceuticals37.38% -81.40% 42.69%
IDEAYA Biosciences -1,157.18%-39.78%-36.25%

Summary

Ironwood Pharmaceuticals beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Zai Lab?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

41.7% of Zai Lab shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Zai Lab had 9 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 12 mentions for Zai Lab and 3 mentions for Ironwood Pharmaceuticals. Zai Lab's average media sentiment score of 0.67 beat Ironwood Pharmaceuticals' score of 0.54 indicating that Zai Lab is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ironwood Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zai Lab
5 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Ironwood Pharmaceuticals presently has a consensus target price of $6.23, indicating a potential upside of 34.75%. Zai Lab has a consensus target price of $37.25, indicating a potential upside of 70.11%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts plainly believe Zai Lab is more favorable than Ironwood Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ironwood Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.57
Zai Lab
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

Ironwood Pharmaceuticals has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Ironwood Pharmaceuticals has a net margin of 37.38% compared to Zai Lab's net margin of -44.91%. Zai Lab's return on equity of -31.15% beat Ironwood Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ironwood Pharmaceuticals37.38% -81.40% 42.69%
Zai Lab -44.91%-31.15%-18.17%

Ironwood Pharmaceuticals has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ironwood Pharmaceuticals$296.15M2.59$24.02M$0.905.14
Zai Lab$460.16M5.95-$175.54M-$1.79N/A

Summary

Zai Lab beats Ironwood Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Vericel?

Vericel (NASDAQ:VCEL) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Vericel has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Vericel currently has a consensus target price of $62.00, indicating a potential upside of 5.85%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 34.75%. Given Ironwood Pharmaceuticals' higher possible upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Vericel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vericel
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.88
Ironwood Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.57

In the previous week, Vericel had 9 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 12 mentions for Vericel and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.54 beat Vericel's score of 0.49 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vericel
6 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ironwood Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ironwood Pharmaceuticals has lower revenue, but higher earnings than Vericel. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$324.17M9.22$16.52M$0.6491.52
Ironwood Pharmaceuticals$296.15M2.59$24.02M$0.905.14

Ironwood Pharmaceuticals has a net margin of 37.38% compared to Vericel's net margin of 10.27%. Vericel's return on equity of 9.09% beat Ironwood Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Vericel10.27% 9.09% 6.68%
Ironwood Pharmaceuticals 37.38%-81.40%42.69%

Summary

Vericel beats Ironwood Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Ironwood Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IRWD vs. The Competition

MetricIronwood PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$775.60M$3.96B$7.49B$11.54B
Dividend YieldN/A3.63%2.47%4.65%
P/E Ratio5.2123.8632.9029.69
Price / Sales2.6214.927.935.25
Price / Cash18.9222.7220.8521.62
Price / Book-7.944.184.403.67
Net Income$24.02M-$23.99M$3.51B$394.15M
7 Day Performance-3.40%-6.63%-5.70%-5.80%
1 Month Performance31.60%-8.49%-6.54%-8.19%
1 Year Performance47.33%-6.30%-2.02%-7.86%

Ironwood Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IRWD
Ironwood Pharmaceuticals
3.0316 of 5 stars
$4.69
-2.0%
$6.23
+33.0%
+53.7%$775.60M$296.15M5.21100
ABBV
AbbVie
3.9146 of 5 stars
$292.63
-0.2%
$297.46
+1.7%
+22.3%$516.70B$61.16B50.3157,000
IRON
Disc Medicine
3.6026 of 5 stars
$82.61
+1.7%
$124.18
+50.3%
-13.1%$3.16BN/AN/A165
IDYA
IDEAYA Biosciences
3.054 of 5 stars
$31.88
-0.5%
$49.55
+55.4%
-21.4%$3.09B$218.71MN/A145
ZLAB
Zai Lab
3.5915 of 5 stars
$26.64
-0.8%
$37.25
+39.8%
+8.0%$3.03B$460.16MN/A1,784

Related Companies and Tools


This page (NASDAQ:IRWD) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners